Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference

scientific article published on 01 November 1998

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IBD.3780040415
P698PubMed publication ID9836088

P2093author name stringA Kornbluth
P433issue4
P921main subjectCrohn's diseaseQ1472
P304page(s)328-329
P577publication date1998-11-01
P1433published inInflammatory Bowel DiseasesQ15749161
P1476titleInfliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference
P478volume4

Reverse relations

cites work (P2860)
Q88946789A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential
Q28571862A pharmacologically active monoclonal antibody against the human melanocortin-4 receptor: effectiveness after peripheral and central administration
Q26865009A review of the impact of biologics on surgical complications in Crohn's disease
Q37233054Antibodies against G-protein coupled receptors: novel uses in screening and drug development
Q35537181BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment
Q82296132Cerebral tubercular lesions in a patient treated with infliximab for Crohn's disease
Q92358318Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease
Q37725721Golimumab and malignancies: true or false association?
Q37606758Incidences of serious infections and tuberculosis among patients receiving anti-tumor necrosis factor-α therapy
Q40046093Infliximab Therapy Leading to Pulmonary Tuberculosis in a Patient With Negative Interferon γ Release Assay (IGRA)-Based QuantiFERON Gold Test
Q94325458Infliximab for the treatment of hidradenitis suppurativa
Q35596600Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County
Q74622961Murine monoclonal anti-tNF antibody administration has a beneficial effect on inflammatory bowel disease that develops in IL-10 knockout mice
Q42934166Recent developments in the surgical management of perianal fistula for Crohn's disease.
Q33555986Restoring the balance: immunotherapeutic combinations for autoimmune disease
Q92918204Single-Molecule 3D Images of "Hole-Hole" IgG1 Homodimers by Individual-Particle Electron Tomography
Q41524475Strictureplasty for Treatment of Crohn's Disease: an ACS-NSQIP Database Analysis
Q55287141TNF-α blockade impairs in vitro tuberculous granuloma formation and down modulate Th1, Th17 and Treg cytokines.
Q64969854Targeting mucosal healing in Crohn's disease: what the clinician needs to know.
Q64980007The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product.
Q92276623The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease
Q48059378The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.
Q37540190The Role of Biosimilars in Inflammatory Bowel Disease
Q60017517The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
Q30304487The relationship between infliximab treatment and lymphoma in Crohn's disease
Q40629396Trends in the Surgical Management of Crohn's Disease.
Q81795147Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients

Search more.